New gene therapy trial targets tough autoimmune conditions
NCT ID NCT07583030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called LVIVO-TaVec400 in 44 people with severe autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis that have not responded to standard therapies. The main goals are to check the treatment's safety and find the right dose. Researchers will also look for early signs that the therapy might help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS (PMS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.